1. Home
  2. UTSI vs ENLV Comparison

UTSI vs ENLV Comparison

Compare UTSI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UTStarcom Holdings Corp.

UTSI

UTStarcom Holdings Corp.

N/A

Current Price

$2.30

Market Cap

23.7M

ML Signal

N/A

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

N/A

Current Price

$0.85

Market Cap

26.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UTSI
ENLV
Founded
1991
2005
Country
China
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
26.6M
IPO Year
2000
1995

Fundamental Metrics

Financial Performance
Metric
UTSI
ENLV
Price
$2.30
$0.85
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
3.1K
11.6M
Earning Date
08-29-2025
11-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,793,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.79
52 Week High
$3.00
$2.10

Technical Indicators

Market Signals
Indicator
UTSI
ENLV
Relative Strength Index (RSI) 44.35 37.50
Support Level $2.00 $0.79
Resistance Level $2.55 $1.25
Average True Range (ATR) 0.07 0.10
MACD -0.03 -0.02
Stochastic Oscillator 54.55 10.39

Price Performance

Historical Comparison
UTSI
ENLV

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Share on Social Networks: